Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative TACE to Prevent Recurrence in Small Hepatocellular Carcinoma
ChiCTR-TRC-08000300Phase 4Completed
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Nov 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epirubicin, fluorouracil and 10-hydroxycamptothecin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Disease-free survival time. Started Nov 2008; status: completed.
02
Drugs
epirubicinfluorouracil10-hydroxycamptothecin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-08000300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-08000300.